Contents

Cancer Research

August 15, 2013 • Volume 73 • Number 16

BREAKING ADVANCES

REVIEWS

PERSPECTIVE

MEETING REPORT

INTEGRATED SYSTEMS AND TECHNOLOGIES

MICROENVIRONMENT AND IMMUNOLOGY

MOLECULAR AND CELLULAR PATHOBIOLOGY

PREVENTION AND EPIDEMIOLOGY

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

TUMOR AND STEM CELL BIOLOGY

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER



The actin cytoskeleton, due to its role in many processes involved in cellular transformation, has long been a sought after anticancer target, yet attempts to develop such compounds have been hampered by unacceptable toxicity. By targeting the other core polymer system of the microfilaments, tropomyosin, it is possible to discriminate between actin filaments required for sarcomeric function and those required for tumor growth. *In silico* modeling shows the predicted association of the first in class anti-tropomyosin compound, TR100, with the C-terminus of a cancer-associated tropomyosin, Tm5NM1. The interaction between Tm5NM1 and TR100 results in disruption of actin filament organization and death of tumor cells, both *in vitro* and *in vivo*. For details, see article by Stehn and colleagues on page 5169.

AACR American Association for Cancer Research

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

73 (16)

Cancer Res 2013;73:4963-5298.